Objective To analyze the efficacy of gemcitabine with or without erlotinib for pancreatic
cancer, and to determine the predictive role of epidermal growth factor receptor (EGFR) and …

Background Erlotinib induced skin toxicity has been associated with clinical benefit in
several tumour types. This phase II study evaluated the efficacy of erlotinib, dose escalated …

BACKGROUND. Erlotinib, in combination with gemcitabine, has shown clinical benefits in
pancreatic adenocarcinoma patients. The presence of EGFR mutations and increased …

4099 Background: Patients with advanced pancreatic cancer who fail first-line gemcitabine-
based therapy have no standard treatment options. Capecitabine (CAPE) has activity in …

Abstract BACKGROUND: National Cancer Institute of Canada Clinical Trials Group PA. 3
(NCIC CTG PA. 3) was a phase 3 study (n= 569) that demonstrated benefits for overall …

Pancreatic cancer is aggressive, chemoresistant, and characterized by complex and poorly
understood molecular biology. The epidermal growth factor receptor (EGFR) pathway is …

Purpose Patients with advanced pancreatic cancer have a poor prognosis and there have
been no improvements in survival since the introduction of gemcitabine in 1996. Pancreatic …

Single agent gemcitabine has been the mainstay of therapy for advanced pancreatic cancer
over the past decade. Multiple trials of newer chemotherapeutic agents both alone and in …

Although erlotinib has become an important therapeutic option in addition to gemcitabine,
the high frequency of KRAS mutations in pancreatic cancer probably limits the benefits. We …

Background A randomized clinical trial has found that the addition of erlotinib to gemcitabine
(GEM-E) for pancreatic cancer led to a modest increase in survival. The aim of this national …